Westlake and Ascend close plants, Chemify opens AI-robotics lab, Formation licenses gusacitinib to Sanofi, and more ...

New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

TORONTO (AP) — U.S. President Donald Trump will arrive Sunday for a Group of Seven summit in a country he has suggested should be annexed and as he wages a ...

Sanofi licenses gusacitinib from Formation Bio. 24 June 2025. Biotechnology. Datroway first US-approved TROP2-directed therapy in lung cancer. 24 June 2025. Company Spotlight. A clinical-stage ...

Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors . Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers ...

ASCO: new Sarclisa data support subcutaneous administration with on-body injector New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational ...

The company’s product pipeline include ASN008, Gusacitinib and Sprifermin. Its pipeline treats atopic dermatitis, chronic hand eczema and knee osteoarthritis. Formation Bio carries out platform such ...

Chronic hand eczema (CHE) is a persistent, inflammatory skin disorder characterised by redness, itching, and the formation of vesicles on the hands that can result in pain and a significant ...